Working Group 4
WEBINAR 2 – March 20th, 2025
This webinar will concentrate on the emerging research across novel precision prevention approaches. The session will highlight not only agents currently under investigation in cancer prevention studies—such as cancer prevention vaccines and therapeutic agents but also those primarily used for other indications, which are showing growing evidence of a cancer preventive role. The subsequent panel discussion will focus on exploring knowledge gaps, challenges, opportunities and the incentives required in advancing precision prevention approaches on the road to implementation for patient/public benefit. The goal of the webinar is to showcase the importance of innovation in precision primary prevention, highlighting the future potential in the field.
March 20th, 2025
1pm to 2:30pm (Paris Time)
David Crosby, head of Prevention and Early Detection research at Cancer Research UK (CRUK)
David Crosby is the Head of Prevention and Early Detection Research at Cancer Research UK. With a background in pharmacology and a PhD in cell signaling, he transitioned from academia to industry, working with Linde Gas Therapeutics, and later joined the UK’s Medical Research Council. At CRUK, he develops strategies to advance cancer prevention and early detection through multidisciplinary research.
Prof. Dr. Matthias Kloor – Senior scientist, Department of Applied Tumor Biology, University Hospital Heidelberg
Dr. Matthias Kloor is acting Director of the Department of Applied Tumor Biology at Heidelberg University Hospital. His main expertise is tumor biology and cancer immune prevention. He leads the Heidelberg University site of the NCI-funded CAP-IT U54 project, focusing on next-generation cancer immunoprevention. He spearheaded the first clinical trial of a frameshift peptide vaccine for MSI cancer patients and is Project Leader of the INDICATE Network, examining the role of HLA genotype in Lynch syndrome.
Dr. Susan M. Domchek – Oncologist at the University of Pennsylvania, Executive Director of the Basser Center for BRCA and Professor in Oncology at the Perelman School of Medicine
Dr. Susan M. Domchek is an oncologist at the University of Pennsylvania, Executive Director of the Basser Center for BRCA, the Basser Professor in Oncology at the Perelman School of Medicine, and Director of the Mariann and Robert MacDonald Cancer Risk Evaluation Program at Penn Medicine. She has authored more than 250 articles in scholarly journals. In 2018, she was elected to the National Academy of Medicine.
Dr. Hormuzd A. Katki – Senior Investigator in the Biostatistics Branch in the NCI
Dr. Hormuzd Katki is a tenured senior investigator in the biostatistics branch of the US national cancer institute. Dr. Katki’s research focuses on cancer screening and prevention and particularly interested in developing individualized prediction-based approaches to cancer screening. He developed risk models for cervical cancer screening that underlie US cervical screening and management guidelines. He has also developed prediction models for use in lung cancer screening that are used in the clinic.
Dr. Andrew R. Reynolds – Senior Director Scientist, AstraZeneca
Dr. Andrew Reynolds is a scientist based in AstraZeneca’s R&D centre in Cambridge, UK. Andrew completed his PhD at the Cancer Research UK London Research Institute in 2002, followed by a Post-doc at Barts Cancer Institute (BCI) from 2002 to 2007. He was then a Group Leader at the Institute of Cancer Research (ICR) in London from 2007 to 2016, before then joining AstraZeneca in 2016. His research at AstraZeneca is focused on premalignant disease and the potential to develop medicines for cancer prevention.